Product Code: RP-ID-10012863 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10012863
Market Overview:
Global Viral Vectors and Plasmid DNA manufacturing market Size study, by Product (Plasmid DNA, Viral Vectors, Non-Viral Vectors), & by Application (Inherited Disorders, Cancers, Viral Infections, & Others) - Forecast 2020
Global Viral Vectors and Plasmid DNA manufacturing market to reach USD 1250.9 million by 2025.
Global Viral Vectors and Plasmid DNA manufacturing market valued approximately USD 281.4 million in 2017 is anticipated to grow with a healthy growth rate of more than 20.5% over the forecast period 2018-2025. The Gene therapy & genetically modified therapies are and pivotal treatment option that consists introduction of a functional copy of gene in the defective cell. The gene therapy has the ability to prevent the individual’s body from the progression of chronic & infectious diseases which includes neurological disorders, infectious pathogen, Cardiovascular diseases, inherited disorders and Cancers. In the present scenario, there are number of systems that displays efficient transfer of therapeutics gene precisely into the targeted cells that includes viral and non-viral vectors. The most common viral vectors utilized in the gene therapy by researchers and medical experts specifically include adenovirus, lentivirus, retrovirus and adeno-associated viral. Likewise, the non-viral vectors precisely rely on the delivery of Plasmid DNA. The inbuilt complexity of the viral based vectors is extremely challengeable to develop the quality vectors considering its physical size, delivery function, physical size and cost. To overcome these concerns the manufacturers of viral vectors opt for a range of approaches aiming the development of vectors that include (cGMP) current good manufacturing practices, development of cell line culture, expression systems and cell culture systems which are ideal for early stage developments. The transfer of focus for the treatment approaches ahead of regenerative medicine has result in constant advancements in the techniques utilized for viral vectors & plasmid DNA manufacturing. The viral vectors are precisely constructed by utilizing helper plasmid, structural plasmid and therapeutic transgene. The benefits of utilizing viral vectors mainly include but are not limited to, limited infection to broad spectrum of cells, low risk of chromosomal integration, easy culture production and stoutness due to process validations. They are also simple to manipulate or mutate.
The viral vector market on the global scenario is mainly characterized by constant technological advancements in the areas which mainly includes rising focus on gene therapy research, escalating research for flexibilities in the scale up approaches for plasmid DNA & viral vector production processes. The viral vector market is also on the surging trend owing to commercial grade products which could be utilized for delivering or providing high doses of biopharmaceutical drugs such as viral vaccines. Although, factors which includes challenges involved in precise maintenance of these cultures & stringent guidelines associated to purification achieved in downstream processes are expected to hamper the growth of viral vectors & plasmid DNA manufacturing market on the global scenario.
The regional analysis of Global Viral Vectors and Plasmid DNA manufacturing market covers four major regions which includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share. Whereas, owing to the countries such as China, Japan, and India, Asia Pacific region is anticipated to exhibit higher growth rate / CAGR over the forecast period 2018-2025.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
• Integrated
• Dedicated
• Hybrid
By Device:
• Computer
• Smartphone
• Gaming Console
• Tablet
• Television
• Others
By Industry Verticals:
• IT & Telecommunication
• Electronics
• Media & Entertainment
• Defense & Intelligence
• Others
By Regions:
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
• Asia Pacific
o China
o India
o Japan
• Latin America
o Brazil
o Mexico
• Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025
The industry is seeming to be fairly competitive. Some of the leading market players include General Electric Company, Finvector vision Therapies, NVIDIA Corporation, Cobra Biologics, Novasep, Fujifilm Holdings Corporation, Finvector Vision Therapies Limited, Kaneka Corporation, Sirion Biotech GmbH, Sigma-Aldrich Co LLC. and so on. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Target Audience of the Global Viral Vectors and Plasmid DNA manufacturing Market in Market Study:
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
Cobra Biologiscs Limited
Finvector Vision Therapies Limited
Fujifilm Holdings Corporation
General Electric Compnay
Kaneka Corporation
Lonza Group
Novasep
Sigma-Aldrich Co. LLC
Sirion Biotech GmbH
VGXI Inc.
Virovek
Related Reports
Proof of Quality & Reliability
